Lipids Blood Markers

Total amount of cholesterol in the blood.

PED: AAS generally worsen lipid profiles. Oral AAS are particularly harsh on lipids. Total cholesterol alone is less meaningful than the HDL/LDL ratio and ApoB.

High-density lipoprotein - 'good' cholesterol that protects against heart disease.

PED: CRITICAL: AAS (especially oral compounds) dramatically suppress HDL, often to dangerously low levels (<0.5 mmol/L). This is one of the most significant cardiovascular risks of AAS use. HDL should be monitored closely and given time to recover between cycles. HDL typically takes 4-8 weeks to recover after dropping oral compounds.

Low-density lipoprotein - 'bad' cholesterol associated with heart disease risk.

PED: AAS typically elevate LDL. Combined with suppressed HDL, this creates an atherogenic profile. ApoB is a more accurate measure of atherogenic particle count than LDL alone.

Type of fat in the blood. Elevated levels increase cardiovascular risk.

PED: Can be elevated by high calorie bulking diets, especially high carb. GH use can worsen triglycerides. Fasted blood draw important for accurate reading (12h fast minimum).

Total cholesterol minus HDL. Captures all atherogenic lipoproteins (LDL, VLDL, IDL).

PED: Better predictor of cardiovascular risk than LDL alone. AAS worsen this marker by suppressing HDL and elevating LDL/VLDL. Target <2.5 mmol/L for primary prevention. ApoB is an even more accurate cardiovascular risk marker -- consider requesting alongside lipid panel.

Ratio of total cholesterol to HDL. Lower is better for cardiovascular health.

PED: AAS users often have very unfavourable ratios due to suppressed HDL. Ratio >5.0 indicates elevated cardiovascular risk. Optimal is <4.0.

Protein found on all atherogenic lipoprotein particles (LDL, VLDL, IDL, Lp(a)). Each particle carries exactly one ApoB molecule, making it a direct count of atherogenic particles. Considered a more accurate cardiovascular risk predictor than LDL alone.

PED: Superior to LDL for assessing cardiovascular risk in PED users. AAS worsen ApoB levels -- oral compounds are particularly harmful. Unlike LDL (which measures cholesterol content), ApoB counts the actual number of atherogenic particles, which better predicts arterial plaque buildup. Target <0.9 g/L for primary prevention, <0.7 g/L for high-risk individuals.

Genetically determined lipoprotein particle. Elevated levels are an independent risk factor for cardiovascular disease, aortic stenosis, and stroke. Levels are ~90% determined by genetics and largely unaffected by lifestyle.

PED: Lp(a) is almost entirely genetic -- AAS, diet, and exercise have minimal effect on levels. However, it is a critical cardiovascular risk marker that every PED user should know once. If elevated (>75 nmol/L or >30 mg/dL), it compounds the already elevated cardiovascular risk from AAS-worsened lipids. Test once -- if normal, no need to retest as levels are stable throughout life.

The primary structural protein of HDL particles. Superior predictor of cardiovascular risk compared to HDL-C because it directly quantifies functional HDL particles.

PED: Oral 17-alpha-alkylated AAS devastate ApoA-1. Stanozolol reduced ApoA-1 by 40% in clinical studies — it upregulates hepatic triglyceride lipase (HTGL) by 230% within 3 days, accelerating HDL catabolism. Injectable testosterone at TRT doses has minimal effect. Nandrolone showed no significant change. Compounds ranked worst to least: Stanozolol > Oxandrolone > Oxymetholone > Trenbolone > Boldenone > Testosterone > Nandrolone. Recovery is slow — ApoA-1 had not returned to baseline 6 weeks after a 14-week cycle.

The balance between atherogenic particles (ApoB) and protective particles (ApoA-1). Considered the single most powerful lipid predictor of cardiovascular risk, superior to any cholesterol ratio.

PED: AAS users get a double hit — ApoB rises (more atherogenic particles) while ApoA-1 drops (fewer protective particles), amplifying the ratio dramatically. A baseline of 0.55 can easily reach 1.2+ on an oral AAS cycle. The INTERHEART study (52 countries) found ApoB/ApoA-1 superior to any cholesterol ratio for predicting myocardial infarction, with a population-attributable risk of 54%. This is the most important single lipid marker for PED users to track.

Total number of LDL particles measured by NMR spectroscopy. More predictive of cardiovascular disease than LDL cholesterol concentration alone.

PED: AAS significantly increase LDL particle number, even when LDL-C appears only mildly elevated. Oral 17-alpha-alkylated steroids have the most pronounced effect. Discordance between LDL-C and LDL-P is common in AAS users — LDL-P often reveals higher cardiovascular risk than LDL-C suggests. Combined with HDL suppression, this creates a highly atherogenic particle profile. Trenbolone is particularly harsh on lipoprotein particle counts.

Mean diameter of LDL particles. Pattern A (large buoyant, >20.5 nm) is less atherogenic; Pattern B (small dense, <20.5 nm) is associated with increased cardiovascular risk.

PED: AAS shift LDL toward small dense Pattern B particles, increasing atherogenicity even when total LDL-C is not dramatically elevated. Oral AAS (stanozolol, oxandrolone) cause the most pronounced shift to small dense LDL. Insulin resistance from GH/insulin use compounds this shift. High triglycerides correlate with smaller LDL. Pattern B + elevated LDL-P is the most concerning combination.

Total number of HDL particles. HDL-P is a stronger predictor of cardiovascular protection than HDL cholesterol concentration.

PED: AAS profoundly suppress HDL-P, often more dramatically than HDL-C. Oral AAS cause the most severe suppression. HDL-P is a better measure of reverse cholesterol transport capacity than HDL-C alone. On-cycle HDL-P values of 15-20 umol/L are common (vs normal >30). Recovery of HDL-P after cycle cessation can take 3-6 months.

Concentration of large VLDL particles. Elevated levels indicate triglyceride-rich lipoprotein overproduction and are strongly linked to insulin resistance.

PED: GH use increases hepatic VLDL production, elevating large VLDL-P. Insulin use (common in advanced bodybuilding) and insulin resistance from GH compound this. High-calorie bulking diets (especially high-carb) drive VLDL production. Oral AAS affect hepatic lipid metabolism, contributing to VLDL elevation. Elevated large VLDL-P correlates strongly with the LP-IR score.

Concentration of large HDL particles. These are the most cardioprotective HDL subclass, responsible for the majority of reverse cholesterol transport.

PED: AAS profoundly reduce large HDL-P — these particles are the first to decline on-cycle. Oral AAS have the most severe impact. Large HDL-P is the HDL subclass most associated with cardiovascular protection. On-cycle values often drop to near-zero. Recovery after cycle cessation is slow (3-6 months). Aerobic exercise is the strongest stimulus for large HDL-P production.

Mean diameter of VLDL particles. Larger VLDL particles are more triglyceride-rich and associated with insulin resistance and metabolic dysfunction.

PED: GH use and insulin resistance increase VLDL size by promoting hepatic production of large triglyceride-rich VLDL. High-calorie bulking diets (especially high-carb) increase VLDL size. Larger VLDL particles are a key driver of the LP-IR insulin resistance score. Combined with insulin and GH use in advanced bodybuilding, VLDL size can be significantly elevated.

Mean diameter of HDL particles. Larger HDL particles are more cardioprotective, associated with better reverse cholesterol transport capacity.

PED: AAS shrink HDL particles by reducing the proportion of large cardioprotective HDL. Smaller HDL is less effective at reverse cholesterol transport. Oral AAS have the most pronounced effect on HDL size. Regular aerobic exercise promotes larger HDL particles. HDL size typically recovers post-cycle alongside HDL-C and HDL-P.

NMR-derived composite score (0-100) reflecting insulin resistance based on lipoprotein particle sizes and concentrations. Higher scores indicate greater insulin resistance.

PED: GH use induces insulin resistance, directly elevating the LP-IR score. Exogenous insulin use (common in advanced bodybuilding) creates a complex picture — insulin sensitivity may be adequate but the lipoprotein profile reflects resistance patterns. Bulking phases with high carbohydrate intake worsen LP-IR. AAS themselves have variable effects on insulin sensitivity, but the combined GH + AAS + high-calorie diet profile commonly seen in bodybuilders often produces elevated LP-IR scores. This marker integrates information from VLDL, LDL, and HDL particle sizes and subclass concentrations.

Calculated ratio of LDL to HDL cholesterol. A higher ratio indicates greater atherogenic risk. Useful as a quick cardiovascular risk assessment.

PED: AAS dramatically worsen this ratio through a dual mechanism: elevating LDL while simultaneously suppressing HDL. Oral 17-alpha-alkylated steroids cause the most severe distortion — ratios of 5-10+ are common on-cycle (vs ideal <2.5). Trenbolone is particularly harsh. Even injectable testosterone at supraphysiological doses worsens this ratio. Post-cycle recovery of this ratio depends primarily on HDL recovery, which can take 3-6 months.

Cholesterol carried by VLDL particles, which transport triglycerides from the liver. Usually estimated from triglycerides via the Friedewald equation (Triglycerides / 5 in mg/dL). Elevated levels indicate excess triglyceride-rich lipoprotein production and increased atherogenic risk.

PED: Oral/17-alpha-alkylated AAS (oxandrolone, stanozolol, methandrostenolone) increase hepatic VLDL production while suppressing HDL, creating a broadly atherogenic profile. GH stimulates hepatic VLDL secretion by enhancing lipolysis and promoting insulin resistance. The combination of oral AAS + GH + high-calorie bulking diets creates maximal VLDL elevation through multiple converging pathways. Lipid effects from AAS are generally reversible, normalising 2.5 to 4 months after discontinuation.

The ratio of fasting triglycerides to HDL cholesterol. Serves as an accessible proxy for insulin resistance and small dense LDL particle predominance. A ratio above 2.0 is associated with insulin resistance and elevated cardiovascular risk; above 3.5 is strongly predictive of metabolic syndrome. Lower is better.

PED: AAS users face a compounded problem: androgens, especially oral compounds, suppress HDL (raising the denominator problem) while high-calorie bulking diets and GH-related insulin resistance elevate triglycerides. MK-677, by chronically elevating GH and IGF-1, produces insulin resistance that worsens fasting triglycerides substantially, often pushing the ratio above 3.0 even without traditional AAS. This ratio is more informative in PED users than in the general population because it integrates both lipid and metabolic dysfunction simultaneously.

Calculated as Total Cholesterol minus LDL minus HDL. Represents the cholesterol content of triglyceride-rich lipoprotein remnants: primarily VLDL remnants (IDL) and chylomicron remnants. An emerging cardiovascular risk marker that predicts atherosclerosis independently of LDL. Desirable level is below 0.5 mmol/L.

PED: AAS broadly disrupt lipoprotein metabolism, increasing hepatic VLDL production and impairing VLDL clearance, which elevates remnant cholesterol even when LDL appears acceptable. GH therapy significantly raises VLDL secretion, directly increasing remnant cholesterol. The Copenhagen Heart Study and Mendelian randomisation data confirm remnant cholesterol predicts cardiovascular events independently of LDL, making it a valuable additional marker for PED users who may have normal LDL but disturbed VLDL metabolism.

Calculated by dividing LDL cholesterol (in mg/dL or mmol/L converted) by ApoB (in mg/dL). Estimates LDL particle size distribution. A ratio above 1.2 suggests predominance of large buoyant LDL particles (less atherogenic); below 1.2 suggests small dense LDL predominance (more atherogenic). Does not require a fasted sample.

PED: AAS users tend toward small dense LDL (pattern B) due to elevated triglycerides and reduced HDL, which activate CETP-mediated cholesterol ester transfer from LDL to VLDL, producing smaller, denser LDL particles. A PED user with LDL of 3.5 mmol/L and an LDL/ApoB ratio of 0.9 has a significantly worse cardiovascular risk profile than someone with the same LDL and a ratio of 1.3. This ratio provides actionable context for interpreting LDL in the setting of AAS-altered lipoprotein metabolism. Units note: when using mmol/L for LDL and g/L for ApoB, multiply LDL by 38.67 to convert to mg/dL for this calculation.

A long-chain omega-3 fatty acid, measured here as its percentage of total fatty acids on a red-blood-cell or plasma fatty-acid panel. EPA is strongly anti-inflammatory and, with DHA, underlies the cardioprotective effects attributed to marine omega-3s.

PED: A low EPA percentage indicates poor omega-3 status and typically tracks with a high omega-6 to omega-3 balance, which is pro-inflammatory. This matters for enhanced athletes on two fronts: AAS worsen the lipid and cardiovascular profile, and raising EPA (via oily fish or fish-oil supplementation) is one of the few evidence-based levers that lowers triglycerides and systemic inflammation without harming the physique. EPA percentage climbs predictably with EPA/DHA intake, so it is a useful way to confirm supplementation is actually working. Values are matrix and method dependent (red-cell panels read differently from plasma), so compare against the reporting lab's range and trend it over time.

A long-chain omega-3 fatty acid measured as a percentage of total fatty acids on a red-blood-cell or plasma panel. DHA is a major structural fat in neural and retinal membranes and, with EPA, drives the cardiovascular and anti-inflammatory benefits of marine omega-3s.

PED: DHA percentage is a marker of omega-3 status and, together with EPA, forms the basis of the Omega-3 Index. A low DHA reflects inadequate marine omega-3 intake and a pro-inflammatory fatty-acid balance. For AAS users, whose lipids and cardiovascular risk are already worsened, improving DHA/EPA status is a cheap, evidence-based support measure that lowers triglycerides and inflammation. DHA is raised most efficiently by oily fish or fish/algal oil. As with all fatty-acid percentages, results depend on the panel matrix (red cell vs plasma), so trend against the same lab's reference.

An intermediate long-chain omega-3 fatty acid that sits metabolically between EPA and DHA. Measured as a percentage of total fatty acids, it acts as a reservoir that can be converted to EPA or DHA and contributes to overall omega-3 status.

PED: DPA is the less-discussed third marine omega-3, alongside EPA and DHA, and it is included in the EPA+DPA+DHA sum that some panels report as their Omega-3 Index. It rises with fish and fish-oil intake and generally moves in parallel with EPA and DHA, so a low DPA usually just reinforces a low overall omega-3 status. There is no separate supplement target for DPA specifically: improving total EPA/DHA intake raises it. As with the other fatty-acid fractions, the percentage is matrix and method dependent.

The principal long-chain omega-6 fatty acid, measured as a percentage of total fatty acids. It is the substrate for many pro-inflammatory eicosanoids, and its level relative to EPA (the AA/EPA ratio) is a widely used index of the body's inflammatory fatty-acid balance.

PED: Arachidonic acid is not villainous in itself: it is essential for membrane function and, in the training world, is even used as a supplement to amplify the inflammatory signalling that supports muscle hypertrophy. The issue for cardiovascular and general inflammatory status is balance, specifically AA relative to EPA. A high AA percentage with a low EPA percentage (a high AA/EPA ratio) reflects a pro-inflammatory milieu, which is unhelpful on top of the cardiovascular strain AAS already impose. The lever is not usually to cut AA but to raise EPA/DHA so the ratio improves. Values are matrix and method dependent.

The most abundant dietary omega-6 fatty acid and an essential fat, measured as a percentage of total fatty acids. It is the parent omega-6 from which arachidonic acid can be synthesised, and it typically makes up a large share of the fatty-acid profile.

PED: Linoleic acid is essential and comes from seed oils, nuts, and seeds, so most people have plenty. On a fatty-acid panel it is usually one of the largest fractions. Contrary to the simple omega-6-is-bad narrative, higher circulating linoleic acid is generally associated with neutral-to-favourable cardiometabolic outcomes; the pro-inflammatory concern applies more to the downstream omega-6 to omega-3 balance than to linoleic acid itself. For enhanced athletes the practical point is simply to keep the overall omega-6 to omega-3 ratio in check by ensuring adequate EPA/DHA, rather than fixating on linoleic acid. Values are matrix and method dependent.

The summed percentage of all omega-3 fatty acids on the panel (typically ALA, EPA, DPA, and DHA) as a fraction of total fatty acids. It is a broad measure of overall omega-3 status, related to but not identical to the Omega-3 Index.

PED: Omega-3 Total is the panel's overall omega-3 sum. It is closely related to the Omega-3 Index but not the same thing: the Omega-3 Index counts specifically red-cell EPA+DHA (some panels EPA+DPA+DHA), whereas the total may also include the plant omega-3 ALA, which is far less biologically active. So a respectable Omega-3 Total driven by ALA can still coexist with a low, suboptimal Omega-3 Index. For cardiovascular purposes the marine EPA/DHA content is what matters, and a red-cell EPA+DHA of about 8% or higher is the cardioprotective target. For AAS users, improving marine omega-3 status is a legitimate, low-cost cardiovascular support measure. Values are matrix and method dependent.

The summed percentage of all omega-6 fatty acids on the panel (chiefly linoleic acid and arachidonic acid) as a fraction of total fatty acids. Omega-6 fats are essential but, in a Western diet, usually abundant, so the informative figure is the omega-6 to omega-3 ratio rather than the total alone.

PED: Omega-6 fats are essential and typically plentiful, so a high Omega-6 Total by itself is rarely the problem; what matters is the omega-6 to omega-3 balance. A high omega-6 total paired with a low omega-3 total gives an elevated omega-6/omega-3 ratio, which favours a pro-inflammatory eicosanoid environment. For AAS users, whose cardiovascular and inflammatory status is already under pressure, keeping that ratio in check by raising EPA/DHA (rather than aggressively cutting essential omega-6s) is the sensible approach. Values are matrix and method dependent.

The ratio of arachidonic acid (omega-6) to EPA (omega-3) in the fatty-acid profile. It summarises the balance between pro-inflammatory and anti-inflammatory eicosanoid precursors, with a lower ratio reflecting a more favourable, less inflammatory balance.

PED: The AA/EPA ratio is arguably the most practically useful single number on an omega fatty-acid panel, because it captures the inflammatory balance in one figure. A high ratio (lots of arachidonic acid, little EPA) indicates a pro-inflammatory state; a lower ratio indicates that omega-3 intake is adequate to offset omega-6. It responds quickly and predictably to fish-oil supplementation, dropping as EPA rises, which makes it a good way to confirm an omega-3 protocol is working. For AAS users this is a cheap, modifiable lever that supports cardiovascular and general inflammatory health without any downside to the physique. Lower is generally better; values are matrix and method dependent.

The ratio of total omega-6 to total omega-3 fatty acids in the profile. It captures the overall dietary fatty-acid balance; a lower ratio reflects a more anti-inflammatory pattern closer to ancestral diets, while typical Western diets sit much higher.

PED: Where the AA/EPA ratio focuses on the specific inflammatory eicosanoid precursors, the omega-6/omega-3 ratio is the broader dietary-balance version. Ancestral intakes were near 1:1 to 4:1, whereas modern Western diets often run 15:1 or higher, a shift linked to greater inflammatory tone. Lowering the ratio is achieved mainly by adding EPA/DHA and moderating industrial omega-6 intake, not by removing essential omega-6 fats. For enhanced athletes this is a straightforward, evidence-based way to support cardiovascular and inflammatory health alongside the harder lipid work. Lower is generally better; values are matrix and method dependent.

The combined percentage of the marine omega-3 fatty acids EPA, DPA, and DHA in red blood cells, essentially the Omega-3 Index. It is the best-validated single measure of long-term marine omega-3 status and a recognised cardiovascular risk marker.

PED: This is the marker that matters most on an omega panel. The Omega-3 Index (red-cell EPA+DHA, often reported with DPA added) has robust outcome data: below about 4% is a high-risk zone for death from coronary heart disease, and 8% or above is the low-risk, cardioprotective target. It reflects months of intake, not the last meal, so it is a stable measure of habitual status. For AAS users, whose cardiovascular risk is elevated by adverse lipid changes, blood-pressure rises, and erythrocytosis, getting the Omega-3 Index into the 8%+ range is one of the clearest, cheapest, evidence-based protective moves available. It rises steadily with EPA/DHA intake, so it is easy to act on and re-measure. Values are matrix and method dependent, but the index is specifically standardised to red cells.

The concentration of medium-sized LDL particles measured by advanced lipoprotein testing (NMR or ion mobility). It is a subfraction of the total LDL particle number, intermediate in size and atherogenicity between large buoyant and small dense LDL.

PED: Medium LDL particles sit between the large, more buoyant LDL and the small, dense, most atherogenic LDL. They contribute to the total atherogenic particle burden (better captured by ApoB and LDL-P), and the clinically important question is usually the shift toward small dense particles rather than the medium fraction alone. AAS, especially oral 17-alpha-alkylated compounds, raise LDL particle number and drive the profile toward smaller, denser particles, so medium and small LDL often rise together on cycle while HDL is suppressed. Interpret this fraction as part of the whole subfraction pattern alongside ApoB, LDL-P, and small LDL. Reference ranges for individual subfractions are strongly method and lab dependent (NMR LipoProfile, ion mobility, and Boston Heart report differently), so trend against the same assay.

The concentration of small, dense LDL particles measured by advanced lipoprotein testing (NMR or ion mobility). Small dense LDL is the most atherogenic LDL subclass: these particles penetrate the arterial wall more readily, are more prone to oxidation, and persist longer in circulation.

PED: Small dense LDL (sdLDL) is the LDL subfraction most strongly tied to cardiovascular risk, over and above total LDL cholesterol. This is a genuine and important harm-reduction marker for enhanced athletes: AAS suppress HDL and shift LDL toward the small, dense phenotype, and oral 17-alpha-alkylated compounds (stanozolol, oxandrolone) and trenbolone are especially bad for it. Insulin resistance from GH/insulin use and high triglycerides push LDL even smaller. So a lean, apparently healthy bodybuilder can show a relatively modest LDL-C while carrying a highly atherogenic small dense LDL burden, which is exactly the discordance advanced lipoprotein testing exists to catch. Read it with ApoB, LDL-P, triglycerides, and HDL. Reference ranges for subfractions are strongly method and lab dependent (NMR LipoProfile, ion mobility, Boston Heart differ), so trend against the same assay rather than a universal cut-off.